|
|
| |
Welcome
Chembio Diagnostic Systems, Inc. (Chembio) (OTCBB: CEMI) develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases. Founded in 1985, Chembio entered the POC testing field in the late 1990's and, in 2002, focused its business to participate in the emerging global need and opportunity for rapid HIV tests. As a result of this focus during the next six years, from 2003 through 2009, Chembio's total revenues grew at a compounded annual growth rate exceeding 30%, approaching $14MM in 2009.
During 2009, Chembio's sales of its rapid HIV tests for the U.S. market through its U.S. marketing partner, Inverness Medical, increased 148% to $5.3MM.
Chembio's Dual Path Platform (DPP®) POC technology was awarded United States Patent No. 7,189,522 in March 2007. DPP® enables development of POC assays that provide unique features and capabilities such as multiplexing and improved control of challenging sample types, such as oral fluid. Several new tests have already been developed on DPP® including a new oral fluid HIV 1/2 test, a new five-band POC confirmatory test for HIV 1/2, and a combination screening and confirmation test for Syphilis. Prototypes of an oral fluid test for Hepatitis C and various strains of influenza have also been developed.
|
The Dual Path Platform (DPP®) Technology
Chembio’s Patented Point-of-Care Testing Platform
|
| |
Dual Path Platform
(DPP®)
The Dual Path Platform (DPP®) Technology (US Patent# 7,189,522) was developed as a platform for next generation, rapid diagnostic testing. Chembio believes that this technology allows the freedom to operate in the POC sector and offers a novel, low-cost, rapid technology as an attractive alternative to established point of care formats including lateral flow. Advantages of DPP include increased analytical and clinical sensitivity, multiplexing capabilities and quantifiable results. The technology is available for application in diverse global diagnostic markets for human and veterinary assays, food safety, bioterrorism, environmental testing, etc. |
 |
| |
| |
DPP Features:
- Increased analytical and clinical sensitivity
- Outside the standard lateral flow IP
- Less labor intensive than EIA, PCR or WB
- Potential ideal confirmatory test
- Adaptable to multiple sample types: blood serum, oral fluid, sputum urine, feces, etc.
- Multiplex capability through elimination of
aggregation issues (ie HIV/TB, HIV 1/ 2, etc.)
- Ideally suited for POC testing
- Requires minimal sample volume
- Long shelf life (up to 24 months)
- Total test time < 20 minutes
|
|
Diverse Potential Applications include:
|
|
|
|
|
| |
|
|
| |
|
|
|
|
|
